Company profile
PYXIS ONCOLOGY, INC.
NASDAQ:PYXSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALDASTOTUG | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05720117 | phase1 | recruiting | 2023-03-14 | 2027-04-25 | Pyxis Oncology, Inc | A Study of PYX-201 in Advanced Solid Tumors |
| NCT06795412 | phase1_2 | recruiting | 2025-04-15 | 2027-12-06 | Pyxis Oncology, Inc | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors |
| NCT05718557 | phase1 | active_not_recruiting | 2023-05-23 | 2026-05-01 | Pyxis Oncology, Inc | Study of PYX-106 in Solid Tumors |
FDA applications (0)
No records yet.